Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01742299 · ClinicalTrials.gov registry record · Phase 4
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
A Phase 4 study of GIST and CML, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 155
- Enrollment target
- 20
- Study locations
NCT01742299: Active Phase 4 study of GIST and CML, sponsored by Novartis Pharmaceuticals.
NCT01742299 is a Phase 4 study of GIST and CML that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 155 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01742299, a Phase 4 study of GIST and CML, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 155 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and are benefiting from the treatment as judged by the investigator.
Primary Outcome
Evaluation of long-term safety based on the frequency and severity of adverse events and serious adverse events occurring during the study.
Conditions Studied
Interventions
- DRUG imatinib mesylate
Study Locations (20)
Other
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Beijing
- Novartis Investigative Site - Guangzhou
- Novartis Investigative Site - Shanghai
- Novartis Investigative Site - Helsinki
- Novartis Investigative Site - Lille
- Novartis Investigative Site - Pessac
- Novartis Investigative Site - Poitiers
- Novartis Investigative Site - Hong Kong
California
- University of California LA - Los Angeles
Illinois
- Northwestern University - Chicago
Maryland
- Sidney Kimmel CCC At JH - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Weill Cornell Medical Center - New York
Oregon
- Oregon Health Sciences University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2013-03-26 |
| Est. Completion | 2033-04-21 |
| Phase | Phase 4 |
What the registry record for NCT01742299 still lists
NCT01742299 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (70% lower).
The record links to 1 condition, with GIST and CML appearing as the primary indexed condition, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT01742299 names 20 study sites across 12 states, led by Other, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01742299 about?
NCT01742299 is a clinical study titled "Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator". The purpose of this study is to allow continued use of imatinib in patients who are on imatinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and are benefiting from the treatment as judged by the investigator.
What is the current status of trial NCT01742299?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 155 participants. The study started on 2013-03-26. Estimated completion is 2033-04-21.
What conditions does trial NCT01742299 study?
This clinical trial studies the following conditions: GIST and CML.
What interventions are being tested in trial NCT01742299?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT01742299?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01742299 being conducted?
This trial has 20 study locations across California, Illinois, Maryland, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01742299's enrollment target sits among peer trials
155 525th of 2000 higher than 1,474 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI